Αρχική World News Clinical Benefit of a Combination of Ipilimumab and Nivolumab in Treatment-Naïve Patients... World News Clinical Benefit of a Combination of Ipilimumab and Nivolumab in Treatment-Naïve Patients with Advanced or Metastatic Non-Clear Cell RCC Από Ogkologos - 15 Απριλίου, 2025 549 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SUNNIFORECAST study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR NExT: Advancing Promising Cancer Therapies from the Lab to Clinical Trials 29 Ιουνίου, 2018 Imiquimod is a Safe and Effective Alternative to Surgery for Vulvar... 5 Μαΐου, 2022 15% of People With Lung Cancer Have an Inherited Mutation for... 15 Αυγούστου, 2022 Consensus on Conceptual Framework for Precision Cancer Medicine in Germany 20 Ιουλίου, 2020 Φόρτωση περισσοτέρων HOT NEWS New on NCI’s Websites for March 2025 Trial Tests Abemaciclib As New Option for Early-Stage Breast Cancer EMA Recommends Granting a Marketing Authorisation Under Exceptional Circumstances for Moxetumomab... Enhertu Marks First Targeted Therapy for HER2-Mutant Lung Cancer